Annual report
4528.TEDINET S100TMQ7
Period2023-04-01 → 2024-03-31
Filed2024-06-21
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 157
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥502.7bn | 2023-04-01 → 2024-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥447.2bn | 2022-04-01 → 2023-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥361.4bn | 2021-04-01 → 2022-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥309.3bn | 2020-04-01 → 2021-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥292.4bn | 2019-04-01 → 2020-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥159.9bn | 2023-04-01 → 2024-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥142.0bn | 2022-04-01 → 2023-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥163.7bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥143.5bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥105.0bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥100.9bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥79.7bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥128.0bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥112.7bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥80.5bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥75.4bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥59.7bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥128.0bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥112.9bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥913.7bn | at 2024-03-31 | Cons. | Assets IFRS |
| Total assets | ¥882.4bn | at 2023-03-31 | Cons. | Assets IFRS |
| Total assets | ¥739.2bn | at 2022-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥745.4bn | at 2021-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥673.4bn | at 2020-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥115.1bn | at 2024-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥134.6bn | at 2023-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥798.6bn | at 2024-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥747.8bn | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥661.7bn | at 2022-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥793.0bn | at 2024-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥741.9bn | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥655.9bn | at 2022-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥634.1bn | at 2021-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥562.5bn | at 2020-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥166.1bn | at 2024-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥96.1bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥69.1bn | at 2022-03-31d | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥61.0bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥69.0bn | at 2020-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥110.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥159.6bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥61.8bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥74.0bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥74.2bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | ¥48.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥100.3bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | ¥6.0bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥57.6bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥10.2bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | −¥89.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥32.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥60.2bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥24.8bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥54.7bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥266.61 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥230.85 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥162.19 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥151.11 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥118.47 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥266.57 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥230.79 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥162.16 | 2021-04-01 → 2022-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥151.09 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥118.45 | 2019-04-01 → 2020-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥1,688.43 | at 2024-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,519.19 | at 2023-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,343.4 | at 2022-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,270.45 | at 2021-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,126.95 | at 2020-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 86.8% | at 2024-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 84.1% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 88.7% | at 2022-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 85.1% | at 2021-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 83.5% | at 2020-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 16.7% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 16.1% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 12.5% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 12.6% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 10.7% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 3,853 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 3,761 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 3,687 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 3,607 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 3,560 | at 2020-03-31d | Cons. | Number of employees |
| Revenue | ¥498.8bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥441.2bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥357.0bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥305.2bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥286.2bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥187.9bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Operating income | ¥152.0bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Ordinary income | ¥188.0bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥150.8bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥121.1bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥86.8bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥70.8bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥198.0bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥148.2bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Net income | ¥152.9bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥117.2bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥94.6bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥76.9bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥69.3bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥847.3bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥804.6bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥661.9bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥669.6bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥599.4bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥97.1bn | at 2024-03-31 | Standalone | Liabilities |
| Total liabilities | ¥119.0bn | at 2023-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥750.2bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥685.6bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥599.2bn | at 2022-03-31d | Standalone | Net assets |
| Net assets / equity | ¥574.6bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥507.7bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥184.8bn | at 2024-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥147.0bn | at 2023-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥318.51 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥239.96 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥190.51 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥154.1 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥137.59 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥318.49 | 2023-04-01 → 2024-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥239.94 | 2022-04-01 → 2023-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥190.49 | 2021-04-01 → 2022-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥154.08 | 2020-04-01 → 2021-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥137.57 | 2019-04-01 → 2020-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥80 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥70 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥56 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥50 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥45 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,597.16 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,403.84 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,226.79 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,150.68 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,016.83 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 88.5% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 85.2% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 90.5% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 85.8% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 84.7% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 21.3% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 18.2% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 16.1% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 14.2% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 13.7% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 498,692,000 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 517,425,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 528,341,000 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 528,341,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 528,341,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 3,437 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 3,381 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 3,354 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 3,319 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 3,287 | at 2020-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 2
| Segment | Item | Period | Value |
|---|---|---|---|
| Pharmaceutical Productsreportable segment | employees | at 2024-03-31 | 3853 pure |
| Pharmaceutical Productsreportable segment | employees | at 2024-03-31 | 3437 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,933
| Item | Context | Value | Unit |
|---|---|---|---|
| Total transactions with owners IFRS | CurrentYearDuration_OtherComponentsOfEquityIFRSMember | -8332000000 | JPY |
| Total transactions with owners IFRS | CurrentYearDuration_RetainedEarningsIFRSMember | -69684000000 | JPY |
| Total transactions with owners IFRS | CurrentYearDuration_EquityAttributableToOwnersOfParentIFRSMember | -86711000000 | JPY |
| Total transactions with owners IFRS | CurrentYearDuration_NonControllingInterestsIFRSMember | -387000000 | JPY |
| Total transactions with owners IFRS | CurrentYearDuration | -87098000000 | JPY |
| Equity IFRS | CurrentYearInstant_ShareCapitalIFRSMember | 17358000000 | JPY |
| Equity IFRS | CurrentYearInstant_CapitalSurplusIFRSMember | 17458000000 | JPY |
| Equity IFRS | CurrentYearInstant_TreasurySharesIFRSMember | -63233000000 | JPY |
| Equity IFRS | CurrentYearInstant_OtherComponentsOfEquityIFRSMember | 53194000000 | JPY |
| Equity IFRS | CurrentYearInstant_RetainedEarningsIFRSMember | 768183000000 | JPY |
| Equity IFRS | CurrentYearInstant_EquityAttributableToOwnersOfParentIFRSMember | 792961000000 | JPY |
| Equity IFRS | CurrentYearInstant_NonControllingInterestsIFRSMember | 5644000000 | JPY |
| Equity IFRS | CurrentYearInstant | 798604000000 | JPY |
| Profit loss before tax IFRS | Prior1YearDuration | 143532000000 | JPY |
| Profit loss before tax IFRS | CurrentYearDuration | 163734000000 | JPY |
| Depreciation and amortization ope cf IFRS | Prior1YearDuration | 17451000000 | JPY |
| Depreciation and amortization ope cf IFRS | CurrentYearDuration | 18140000000 | JPY |
| Impairment losses reversal of impairment losses ope cf IFRS | Prior1YearDuration | 1498000000 | JPY |
| Impairment losses reversal of impairment losses ope cf IFRS | CurrentYearDuration | 14885000000 | JPY |
| Interest and dividend income ope cf IFRS | Prior1YearDuration | -2402000000 | JPY |
| Interest and dividend income ope cf IFRS | CurrentYearDuration | -3574000000 | JPY |
| Interest expenses ope cf IFRS | Prior1YearDuration | 74000000 | JPY |
| Interest expenses ope cf IFRS | CurrentYearDuration | 92000000 | JPY |
| Decrease increase in inventories ope cf IFRS | Prior1YearDuration | -2945000000 | JPY |
| Decrease increase in inventories ope cf IFRS | CurrentYearDuration | -3420000000 | JPY |
| Decrease increase in trade and other receivables2 ope cf IFRS | Prior1YearDuration | -14513000000 | JPY |
| Decrease increase in trade and other receivables2 ope cf IFRS | CurrentYearDuration | -19782000000 | JPY |
| Increase decrease in trade and other payables2 ope cf IFRS | Prior1YearDuration | 13090000000 | JPY |
| Increase decrease in trade and other payables2 ope cf IFRS | CurrentYearDuration | -1835000000 | JPY |
| Increase decrease in retirement benefit liability ope cf IFRS | Prior1YearDuration | 214000000 | JPY |
| Increase decrease in retirement benefit liability ope cf IFRS | CurrentYearDuration | -22000000 | JPY |
| Decrease increase in retirement benefit asset ope cf IFRS | Prior1YearDuration | 27000000 | JPY |
| Decrease increase in retirement benefit asset ope cf IFRS | CurrentYearDuration | － | JPY |
| Increase decrease in consumption taxes payable ope cf IFRS | Prior1YearDuration | 5564000000 | JPY |
| Increase decrease in consumption taxes payable ope cf IFRS | CurrentYearDuration | -3899000000 | JPY |
| Other changes in working capital ope cf IFRS | Prior1YearDuration | 2347000000 | JPY |
| Other changes in working capital ope cf IFRS | CurrentYearDuration | 197000000 | JPY |
| Subtotal ope cf IFRS | Prior1YearDuration | 163935000000 | JPY |
| Subtotal ope cf IFRS | CurrentYearDuration | 164517000000 | JPY |
| Interest received ope cf IFRS | Prior1YearDuration | 53000000 | JPY |
| Interest received ope cf IFRS | CurrentYearDuration | 221000000 | JPY |
| Dividends received ope cf IFRS | Prior1YearDuration | 2334000000 | JPY |
| Dividends received ope cf IFRS | CurrentYearDuration | 2445000000 | JPY |
| Interest paid ope cf IFRS | Prior1YearDuration | -74000000 | JPY |
| Interest paid ope cf IFRS | CurrentYearDuration | -92000000 | JPY |
| Income taxes paid ope cf IFRS | Prior1YearDuration | -6637000000 | JPY |
| Income taxes paid ope cf IFRS | CurrentYearDuration | -56431000000 | JPY |
| Net cash provided by used in operating activities IFRS | Prior1YearDuration | 159610000000 | JPY |
| Net cash provided by used in operating activities IFRS | CurrentYearDuration | 110660000000 | JPY |
| Purchase of property plant and equipment inv cf IFRS | Prior1YearDuration | -5340000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |